News Spyre deprioritises arthritis drug after Phase 2 results Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.
News Sanofi pays $180m for rights to Kali autoimmune drug Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
News Quell takes new Treg into clinic after transplant study halt Quell Therapeutics changes tack, starting trials of a CAR-Treg in rheumatoid arthritis and systemic sclerosis and parking its transplant therapy.
News MSD advances on a broad front with TL1A drug tulisokibart MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.
News Istesso backer sees silver lining in failed arthritis trial Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.
News Apple devices enrich patent data in arthritis trial It can be challenging to follow the course of rheumatoid arthritis accurately in clinical assessments and trials due to “subtle and unpredictable” changes in symptoms – bu
News Amgen's Imdelltra scores again in small cell lung cancer Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
